EUVIMEDEUVIMED entdecken
Crossref

Current perspectives on the management of corneal endothelial disease

Sanjay V Patel

Journal of Cornea and Ocular Surface · 2023

DOI: 10.4103/jcos.jcos_11_22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cornea and Ocular Surface, 2023. Verfasst von Sanjay V Patel. Die Arbeit nennt 42 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid advances in the management of corneal endothelial disease have occurred over the last 2 decades, creating a plethora of treatment options and hopes for future minimally invasive and medical treatments. The interest in this area has been spurred in part by the evolution of surgical treatments, from penetrating keratoplasty (PK) to endothelial keratoplasty (EK) and more recently to Descemet-stripping only (DSO), and in part by our improved understanding of the underlying mechanisms of disease, most notably for Fuchs endothelial corneal dystrophy (FECD). Rather than providing a comprehensive review of recent literature in this field, the goal of this perspective is to assess three current and specific topics in the management of corneal endothelial disease and their potential healthcare value for patients by considering the best available evidence. Value-based healthcare is simply defined as patient outcome per cost unit.[1] Cost refers to the overall cost of care related to a disease rather than any specific or isolated intervention and therefore considers outcomes over the longer term (ideally 10 years or more for corneal endothelial disease). Patient outcomes should be defined according to the disease being treated, and these include measures of efficacy, safety, and patient experience. While defining true value in our practices is neither simple nor practical on an individual patient level, considering the factors that affect value in conjunction with the assessment of individual patient situations can help determine the best management approach. The latter requires knowledge of the best current evidence to aid with clinical decision-making. In the setting of corneal endothelial disease, affected patients should have clinically significant disease such that they would be symptomatic; otherwise, corneal interventions are unnecessary and of low value. Therefore, establishing the likelihood that disease is significant is important though not always easy. Symptomatic patients usually have poor or impaired vision, but separating poor vision caused by endothelial disease from that caused by other ocular comorbidities, such as cataract, can often be challenging. Occasionally the major symptom is pain from epithelial bullae in the setting of good or poor visual potential, and this is easier to discern in clinical practice compared to assessing vision. From the patient’s perspective, the best value is derived by improving or alleviating their symptoms, whether vision or pain, for as long as possible while minimizing the overall cost of care, that is, minimizing the number of interventions, complications, medications, patient visits, etc. over the duration of care, which can be for years or even decades after corneal transplantation. This perspective will discuss specific current hot topics in the management of corneal endothelial disease with respect to value-based care. Because the most common corneal endothelial diseases are FECD and postoperative corneal edema (POCE), this perspective focuses on management related to these conditions. POCE is defined as edema arising from previous cataract surgery (pseudophakic or aphakic corneal edema), incisional glaucoma surgery, or other intraocular surgery in the absence of guttae. Image-Based Clinical Decision-Making for Fuchs Endothelial Corneal Dystrophy For the management of FECD, a long-standing clinical challenge has been determining which eyes can benefit from cataract surgery alone and which eyes need combined cataract extraction and keratoplasty. In the PK era, the decision was easier as most surgeons deferred PK unless the cornea was visibly edematous on clinical examination.[2,3] However, because EK offers improved visual outcomes and safety compared to PK,[4] the threshold for intervention has been lowered such that edema is not always visible on clinical examination yet is still present and visually significant.[5] Despite improved safety, not all eyes with guttae require EK, and therefore the decision to proceed to EK should be based on additional objective information and not simply the presence of guttae.[6] Vision is definitely affected in FECD when edema is present; in contrast, many eyes with guttae in the absence of edema attain excellent vision.[7] When corneal edema is not detectable with slit-lamp biomicroscopy, neither corneal pachymetry nor endothelial imaging can reliably determine which corneas are already impacted by early corneal edema or are at risk of decompensation after cataract surgery. Many clinicians have used subjective clinical judgment or poorly derived cut-offs[8] to make the decision of whether to proceed to keratoplasty. As a result, overtreated patients who receive EK when not required have increased cost of care of the procedure, follow-up visits, postoperative pharmacologic therapy, and management of any associated complications, all without improving their visual outcome over cataract surgery alone. In addition, future graft failure would require additional intervention, and therefore the overall value conferred to these patients is very low. Similarly, undertreated patients, i.e., those who do not receive EK when it would be beneficial, deal with suboptimal vision outcomes after cataract surgery, additional postoperative care, and the need for a second surgery (subsequent EK). Again, the overall cost of care would be higher than necessary, and patient satisfaction and experience would be less than ideal, contributing to suboptimal value. The challenge above has been greatly simplified by using Scheimpflug tomography to evaluate corneas with FECD for the presence of subclinical corneal edema, i.e., edema that is present but not biomicroscopically visible.[5] With this imaging modality, earlier stages of corneal edema can be detected than was previously possible, and the method provides an objective assessment instead of relying on subjective instinct. Scheimpflug tomography is indicated in Fuchs dystrophy when corneal edema is not detectable biomicroscopically, that is, by slit-lamp examination. If corneal edema is biomicroscopically detectable, then clinical management is obvious, i.e., benefit will be derived from EK. However, when corneal edema is not biomicroscopically detectable, tomography is indicated to detect the presence of subclinical edema by examining posterior elevation and pachymetry maps for three specific features.[5] These features are the loss of parallel circular/oval isopachs (which are lines joining points of equal thickness), displacement of the thinnest point >1 mm from the center or anywhere outside of the inferotemporal quadrant, and posterior surface depression (i.e., negative elevation) towards the anterior chamber within the central 3–4 mm of the cornea. Determining whether subclinical (or tomographic) edema is present is important for two reasons that greatly facilitate clinical decision-making. First, it is much more likely that corneal disease progression will occur within a few years after cataract surgery alone when subclinical edema is present compared to when it is not (75%–90% risk of progression over 4–5 years).[9] In contrast, when tomography maps are normal, the risk of corneal disease progression is less than 10% over the next 5 years,[9] indicating that EK (or other treatments for the cornea) can reasonably be deferred knowing that most corneas in this category will not need intervention for several years. Second, vision is more likely to be impaired when subclinical edema is present compared to when it is not.[7] In otherwise healthy pseudophakic eyes with FECD, several different domains of vision did not differ from normal eyes when tomography maps were normal. Therefore, normal tomography maps in FECD (without other comorbidities) should confer good vision after cataract surgery alone, and corneal surgical intervention would also not be expected for several years, if at all. This creates excellent value for patients who derive the best vision outcome without needing EK or by appropriately deferring EK and, therefore, the associated costs of care by several years. Scheimpflug tomography analysis of eyes with FECD is rapidly being adopted by cornea specialists and should also become the standard of care for any cataract surgeon, assuming the technology is available to them. The method is objective, repeatable,[10] and independent of central corneal thickness (CCT), that is, interpreting patterns is more helpful than specific thickness measurements.[6,11] Some studies suggest that optical coherence tomography of the cornea also has the potential to provide similar information to Scheimpflug tomography.[12,13] The most important ancillary test in the evaluation of FECD has become tomography, whereas endothelial photography and isolated measurements of CCT provide little useful clinical information. Tomography helps guide which eyes with FECD may benefit from EK and therefore helps improve value for patients. Endothelial Keratoplasty in Complex Eyes The two most common choices of EK are Descemet-stripping endothelial keratoplasty (DSEK) and Descemet membrane endothelial keratoplasty (DMEK). In eyes with ideal anatomy, there is sufficient evidence that DMEK offers better and faster vision recovery[14,15] and similar graft survival compared to after DSEK.[16,17] Therefore, DMEK offers better value than DSEK for patients with eyes with ideal anatomy. However, in eyes with complex anatomy, defined as those that have undergone previous glaucoma drainage device (GDD) implantation, trabeculectomy, vitrectomy, or have a compromised lens-iris diaphragm, there is a paucity of longer term outcomes data of each surgery.[18] Although DSEK can have its challenges in such complex eyes, manipulation of the donor tissue is generally less complicated than that of DMEK donor tissue in complex eyes. Intraoperative difficulties with graft manipulation increase donor endothelial cell loss and the risk of subsequent graft failure, and therefore reducing intraoperative donor manipulation is an important risk factor that is within the surgeon’s control.[19,20] Complex eyes also have a higher likelihood of DSEK graft dislocation that further increases endothelial cell loss because of the need for re-bubble procedures with or without additional direct donor tissue manipulation.[18] However, DSEK graft dislocation can be significantly mitigated by suturing the donor to the host, reducing the need for postoperative intervention and, therefore, potentially reducing endothelial cell loss.[21] DMEK can be very challenging in eyes with complex anatomy because of difficulties with unscrolling the donor tissue in anterior chambers that cannot be easily shallowed (from previous vitrectomy or GDD placement) and because of poor postoperative retention of the gas bubble in the anterior chamber. Unlike DSEK grafts, DMEK grafts cannot be sutured to the host without potentially tearing the tissue. Therefore, in addition to more difficult intraoperative graft manipulation, the need for rebubble procedures is higher after DMEK than after DSEK in complex eyes, further contributing to higher early endothelial cell loss.[22-24] Higher earlier endothelial cell loss, whether from intraoperative challenges, early postoperative complications, or from other tissue-related factors, increases the risk of graft failure[19] and therefore, the increased difficulty of DMEK over DSEK in complex eyes probably contributes to worse graft survival. Indeed, DMEK graft survival in eyes with previous GDD implantation was 67% at 2 years[23] and 27% at 4 years,[24] much lower than that after DSEK in complex eyes (52% at 5 years and 28% at 10 years).[18] Although DMEK has a slight advantage over DSEK with respect to vision outcomes, that advantage has been shown in otherwise healthy (non-complex) eyes that can resolve the difference in acuity.[14,15] In complex eyes with glaucoma, previous vitrectomy, or previous complicated cataract surgery, it is more likely that the best vision is limited by optic neuropathy or maculopathy, and the small visual outcome advantage of DMEK is probably not attained very frequently. In fact, in one series, vision outcomes after DMEK in eyes with previous glaucoma surgery were worse than in otherwise healthy eyes, with most attaining visual acuity in the range that would be expected after DSEK.[25] Current evidence, therefore, suggests that DSEK confers better graft longevity compared to DMEK and can offer sufficient vision in the setting of ocular comorbidities in complex eyes. Attaining the most optimized level of vision for the longest period is what creates the highest value to patients in this situation, and even if DMEK does provide slightly better vision in these eyes compared to DSEK, DSEK offers an excellent compromise between the level of vision and long-term graft survival to confer the greatest value. DSEK is, therefore, a very appropriate, if not more advantageous, surgery than DMEK in complex eyes. The main disadvantage of DSEK over DMEK in complex eyes might be the higher risk of rejection from increased foreign antigenic load in the donor tissue[26]; rejection risk is already higher than normal in eyes with glaucoma.[18] However, it is possible that thinner DSEK tissue should lessen the risk of rejection by transferring less foreign antigen, though data to support this hypothesis are lacking. Another EK option for complex eyes is pre-Descemet endothelial keratoplasty (PDEK).[27] PDEK donor tissue is easier to manipulate than DMEK donor tissue and, therefore, could provide a good compromise between maximizing vision and prolonging graft survival in complex eyes. However, there is a paucity of longer term outcomes data after PDEK, and therefore it is unknown whether PDEK confers improved value over DSEK. In addition, while DSEK may have a current advantage over DMEK in complex eyes, improved delivery techniques and DMEK graft adhesion could tilt the balance in favor of DMEK in the future. Alternative Therapies to Endothelial Keratoplasty The management of corneal endothelial disease has evolved towards non-keratoplasty surgery and even medical therapy.[28] DSO involves the stripping of host Descemet membrane and endothelium without replacement by donor tissue[29-31] and is frequently combined with the administration of topical pharmacologic therapy.[32] Clinical trials are also in progress, evaluating other novel medical therapies to slow or stop the progression of FECD. While these treatments are specific to FECD, intracameral cell injection of cultured corneal endothelial cells, which is also in early clinical trials, has the potential to treat all endothelial cell diseases. Nevertheless, many questions remain unanswered about these procedures with respect to long-term outcomes, costs, and comparative efficacy to currently accepted treatments. DSO can restore improved corneal endothelial function in some eyes with FECD. The procedure typically involves stripping the central 4 mm of Descemet membrane without disrupting underlying posterior stromal fibers and allowing repopulation of the central stripped area by host endothelial cells.[33] While the cells that repopulate the central endothelial defect are primarily peripheral corneal endothelial cells that have migrated to the center,[34] limited cell proliferation in vivo cannot be excluded.[35] Successful treatment, therefore, requires a healthy population and density of peripheral endothelial cells, which is not the case in POCE, and therefore DSO is not a treatment for POCE. Advantages of DSO include not requiring donor tissue, minimal surgical manipulation, no risk of rejection, and, consequently, lower long-term use of topical corticosteroids. However, postoperative corneal clearance is often slow (and inconvenient for many patients) and sometimes incomplete, though both of these disadvantages are potentially improved with the addition of topical rho kinase inhibitors.[36] Sufficient long-term outcomes data are sparse, currently with less than 10 cases described at 5 years.[34,37] The rate of secondary EK is unknown, and comprehensive analyses to determine postoperative visual function (including contrast sensitivity, low-contrast acuity, and disability glare) and the resolution of subclinical edema are lacking.[36,38] Central endothelial cell density typically remains lower than normal, suggesting that subclinical edema, and its associated effects on vision, might persist or redevelop sooner than desired.[34,36] Not all patients with FECD are candidates for DSO, especially those with >4 mm of central guttae and those with obvious corneal edema.[33,38] Of the remaining potential candidates, assessment by Scheimpflug tomography is necessary because most patients with normal tomography would also have normal vision and a good prognosis; these patients would not require DSO or other corneal intervention.[7,9] With outcomes data limited to very small series with 12 months of follow-up only,[38] the value of DSO to patients has not yet been well established, and randomized controlled trials comparing DSO to DMEK are lacking to determine comparative efficacy. While the advantages of DSO would contribute to improved safety and lower procedural costs, it is unknown if the visual outcomes are superior to those after DMEK and for how long. Furthermore, if rescue DMEK is required, it is unknown if lower peripheral endothelial cell density (because of previous cell migration to the center after DSO) at the time of DMEK portends toward reduced graft survival (similar to why graft survival is worse after keratoplasty for POCE compared to FECD[39,40]). Before DSO can be broadly adopted, much more outcomes data are needed to better understand its role in the treatment of FECD and the value it might offer to patients. Future management of corneal endothelial disorders is likely to involve medical therapy, gene therapy, or cell injection therapy.[28] Medical and gene therapies are more likely to play a role in the management of FECD by slowing the progression of disease through targeted approaches and are less likely to be effective for POCE (based on our current understanding of its disease mechanisms). In contrast, cultured corneal endothelial cell injection therapy has the potential to treat all endothelial diseases and could pave the way toward autologous therapy.[41,42] Unlike advances in surgical techniques from PK to DSEK to DMEK, etc., the development of medical, gene, and cell injection therapies will be costly and regulated, requiring the demonstration of safety and efficacy in carefully controlled clinical trials. Assuming these therapies prove to be efficacious at preserving or restoring good vision, the cost of care will probably significantly increase, at least initially. Furthermore, given the duration of medical therapy is likely to be ongoing for FECD, the cost of care will accumulate over time and will only be justified if conversion to surgical treatment is avoided or significantly delayed. Conclusions The management of corneal endothelial diseases continues to evolve along a rapid trajectory, with new treatment options being evaluated or forthcoming. Therefore, determining the ideal treatment for any individual patient from the current armamentarium can be challenging. Adopting an evidence- and value-based approach can facilitate clinical decision-making to confer the best long-term option to patients. This approach might feel conservative to some, and indeed a balance is needed between pioneering new treatments to advance the field while also respecting the needs of the patient and the gift of corneal donor tissue, which is not readily available in most parts of the world. Medical therapeutic advances will only be made available after regulatory approval based on safety and efficacy in carefully controlled clinical trials. In contrast, advances in surgic

Zitieren

APA

Patel, S. V. (2023). Current perspectives on the management of corneal endothelial disease. Journal of Cornea and Ocular Surface. https://doi.org/10.4103/jcos.jcos_11_22

Vancouver

Patel SV. Current perspectives on the management of corneal endothelial disease. Journal of Cornea and Ocular Surface. 2023. doi:10.4103/jcos.jcos_11_22

BibTeX
@article{Patel2023,
  author = {Patel, Sanjay V},
  title = {Current perspectives on the management of corneal endothelial disease},
  journal = {Journal of Cornea and Ocular Surface},
  year = {2023},
  doi = {10.4103/jcos.jcos_11_22}
}
Kostenlos starten →